Search

Your search keyword '"Lalezari J"' showing total 207 results
Start Over Author "Lalezari J"
207 results on '"Lalezari J"'

5. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study)

Author

Lataillade, M., Lalezari, J., Aberg, J., Molina, J-M., Kozal, M., Cahn, P., Thompson, M., Diaz, R., Castagna, A., Gummel, M., Gartland, M., Pierce, A., Ackerman, P., Llamoso, C., Lataillade, M., Lalezari, J., Aberg, J., Molina, J-M., Kozal, M., Cahn, P., Thompson, M., Diaz, R., Castagna, A., Gummel, M., Gartland, M., Pierce, A., Ackerman, P., and Llamoso, C.

Published
2019

9. MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Author

Poordad, F., primary, Pol, S., additional, Asatryan, A., additional, Buti, M., additional, Shaw, D., additional, Hézode, C., additional, Lalezari, J., additional, Felizarta, F., additional, Reindollar, R.W., additional, Gordon, S.C., additional, Pianko, S., additional, Fried, M.W., additional, Bernstein, D.E., additional, Gallant, J., additional, Lin, C.-W., additional, Lei, Y., additional, Ng, T.I., additional, Pilot-Matias, T., additional, Kort, J., additional, and Mensa, F., additional

Published
2017
Full Text
View/download PDF

10. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients

Author

Drew, W.L., Anderson, R., Lang, W., Miner, R.C., Davis, G., and Lalezari, J.

Subjects
Cytomegalovirus infections -- Drug therapy, Acyclovir -- Evaluation, HIV patients -- Care and treatment, Health
Abstract

The drug acyclovir may not prevent or suppress cytomegalovirus infection in symptomatic HIV-positive patients. Researchers divided 93 HIV-positive patients into two treatment groups. The first group received 600 milligrams of zidovudine (ZDV) each day and 4,800 mg of acyclovir per day, while the second group took 600 mg of ZDV per day and a placebo. Patients in the acyclovir group excreted cytomegalovirus (CMV) in their urine, indicating that acyclovir did not prevent reactivation of CMV in these patients. These patients had CD4 cell counts exceeding 200. Treatment with acyclovir for over a year did not cause CMV to become resistant to the drug ganciclovir.

Published
1995

13. High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection

Author

Poordad, F., primary, Felizarta, F., additional, Wang, S., additional, Asatryan, A., additional, Hassanein, T., additional, Aguilar, H., additional, Lalezari, J., additional, Overcash, J.S., additional, Ng, T.I., additional, Lovell, S.S., additional, Lin, C.-W., additional, Kort, J., additional, and Mensa, F.J., additional

Published
2016
Full Text
View/download PDF

15. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

Author

Muir, AJ, Poordad, F, Lalezari, J, Everson, G, Dore, GJ, Herring, R, Sheikh, A, Kwo, P, Hézode, C, Pockros, PJ, Tran, A, Yozviak, J, Reau, N, Ramji, A, Stuart, K, Thompson, AJ, Vierling, J, Freilich, B, Cooper, J, Ghesquiere, W, Yang, R, McPhee, F, Hughes, EA, Swenson, ES, Yin, PD, Muir, AJ, Poordad, F, Lalezari, J, Everson, G, Dore, GJ, Herring, R, Sheikh, A, Kwo, P, Hézode, C, Pockros, PJ, Tran, A, Yozviak, J, Reau, N, Ramji, A, Stuart, K, Thompson, AJ, Vierling, J, Freilich, B, Cooper, J, Ghesquiere, W, Yang, R, McPhee, F, Hughes, EA, Swenson, ES, and Yin, PD

Abstract

IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), asunaprevir (NS3 protease inhibitor), and beclabuvir (nonnucleoside NS5B inhibitor), with or without ribavirin, was evaluated in patients with HCV genotype 1 infection and compensated cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: The UNITY-2 study was conducted between December 2013 and October 2014 at 49 outpatient sites in the United States, Canada, France, and Australia. Patients were treated for 12 weeks, with 24 weeks of follow-up after completion of treatment. Adult patients with cirrhosis were enrolled in 2 cohorts: HCV treatment-naive or HCV treatment-experienced. Statistical analyses were based on historical controls; there were no internal controls. INTERVENTIONS: All patients received twice-daily treatment with the fixed-dose combination of daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg). In addition, patients within each cohort were stratified according to HCV genotype 1 subtype (1a or 1b) and randomly assigned (1:1) to receive double-blinded weight-based ribavirin (1000-1200 mg/d) or matching placebo. MAIN OUTCOMES AND MEASURES: Sustained virologic response at posttreatment week 12 (SVR12). RESULTS: One hundred twelve patients in the treatment-naive group and 90 patients in the treatment-experienced group were treated and included in the analysis. Enrolled patients were 88% white with a median age of 58 years (treatment-naive group) or 60 years (treatment-experienced group); 74% had genotype 1a infection. SVR12 rates were 98% (97.5%CI, 88.9%-100%) for patients in the treatment-naive group and 93% (97.5% CI, 85.0%-100.0%) for those in the treatment-experienced group when ribavirin was included in the regimen. With the fixed-dose combination alone, response rates were 93% (97.5% CI, 85.

Published
2015

18. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome

Author

Lalezari, S, Chou, AP, Tran, A, Solis, OE, Khanlou, N, Chen, W, Li, S, Carrillo, JA, Chowdhury, R, Selfridge, J, Sanchez, DE, Wilson, RW, Zurayk, M, Lalezari, J, Lou, JJ, Ormiston, L, Ancheta, K, Hanna, R, Miller, P, Piccioni, D, Ellingson, BM, Buchanan, C, Mischel, PS, Nghiemphu, PL, Green, R, Wang, HJ, Pope, WB, Liau, LM, Elashoff, RM, Cloughesy, TF, Yong, WH, and Lai, A

Subjects
neoplasms
Abstract

BackgroundPromoter methylation of the DNA repair gene, O-6-methylguanine- DNA methyltransferase (MGMT), is associated with improved treatment outcome for newly diagnosed glioblastoma (GBM) treated with standard chemoradiation. To determine the prognostic significance of MGMT protein expression as assessed by immunohistochemistry (IHC) and its relationship with methylation, we analyzed MGMT expression and promoter methylation with survival in a retrospective patient cohort.MethodsWe identified 418 patients with newly diagnosed GBM at University of California Los Angeles Kaiser Permanente Los Angeles, nearly all of whom received chemoradiation, and determined MGMT expression by IHC, and MGMT promoter methylation by methylation-specific PCR (MSP) and bisulfite sequencing (BiSEQ) of 24 neighboring CpG sites.ResultsWith use of the median percentage of cells staining by IHC as the threshold, patients with

Published
2013
Full Text
View/download PDF

19. P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study

Author

Kowdley, K., primary, Nelson, D., additional, Lalezari, J., additional, Box, T., additional, Gitlin, N., additional, Poleynard, G., additional, Rabinovitz, M., additional, Ravendhran, N., additional, Sheikh, A., additional, Siddique, A., additional, Bhore, R., additional, Yin, P.D., additional, Noviello, S., additional, and Rana, K., additional

Published
2015
Full Text
View/download PDF

20. P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV

Author

Rockstroh, J.K., primary, Nelson, M., additional, Katlama, C., additional, Lalezari, J., additional, Mallolas, J., additional, Bloch, M., additional, Matthews, G., additional, Saag, M., additional, Zamor, P., additional, Orkin, C., additional, Gress, J., additional, Klopfer, S., additional, Platt, H., additional, Robertson, M., additional, and Sulkowski, M., additional

Published
2015
Full Text
View/download PDF

21. Pharmakokinetik (PK) von Etravirin (ETR) mit und ohne Darunavir/Ritonavir (DRV/r) einmal täglich bei nicht antiretroviral vorbehandelten Patienten

Author

Lalezari, J, de Jesus, E, Osiyemi, O, Ranneberg, B, Ruane, P, Haigney, Z, Ryans, R, Polsonetti, B, Kakuda, TN, and Witek, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: Etravirin (ETR) ist wirksam gegenüber HIV-Wildtyp (mit einer EC50 von 4 ng/ml (adjustiert für Proteinbindung)), hat eine terminale Halbwertzeit von 30-40 Stunden und ist daher für eine einmal tägliche (qd) Dosierung geeignet. Im Vergleich der ein- und zweimal täglichen[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010
Full Text
View/download PDF

22. Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

Author

Wei, DG, Chiang, V, Fyne, E, Balakrishnan, M, Barnes, T, Graupe, M, Hesselgesser, J, Irrinki, A, Murry, JP, Stepan, G, Stray, KM, Tsai, A, Yu, H, Spindler, J, Kearney, M, Spina, CA, McMahon, D, Lalezari, J, Sloan, D, Mellors, J, Geleziunas, R, Cihlar, T, Wei, DG, Chiang, V, Fyne, E, Balakrishnan, M, Barnes, T, Graupe, M, Hesselgesser, J, Irrinki, A, Murry, JP, Stepan, G, Stray, KM, Tsai, A, Yu, H, Spindler, J, Kearney, M, Spina, CA, McMahon, D, Lalezari, J, Sloan, D, Mellors, J, Geleziunas, R, and Cihlar, T

Abstract

Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC50 = 4.5 nM) compared with vorinostat (VOR; EC50 = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC50 = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 μM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART.

Published
2014

23. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

Author

Glesby, M. J., primary, Watson, W., additional, Brinson, C., additional, Greenberg, R. N., additional, Lalezari, J. P., additional, Skiest, D., additional, Sundaraiyer, V., additional, Natuk, R., additional, Gurtman, A., additional, Scott, D. A., additional, Emini, E. A., additional, Gruber, W. C., additional, and Schmoele-Thoma, B., additional

Published
2014
Full Text
View/download PDF

25. O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY

Author

Esteban, R., primary, Nyberg, L., additional, Lalezari, J., additional, Ni, L., additional, Doehle, B., additional, Kanwar, B., additional, Brainard, D., additional, Subramanian, M., additional, Symonds, W.T., additional, McHutchison, J.G., additional, Rodriquez-Torres, M., additional, and Zeuzem, S., additional

Published
2014
Full Text
View/download PDF

26. P738 NO CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN FALDAPREVIR AND PEGYLATED INTERFERON a-2a PLUS RIBAVIRIN IN HCV-INFECTED PATIENTS: PHARMACOKINETIC ANALYSES FROM TWO PHASE II STUDIES

Author

Bourlière, M., primary, Sulkowski, M., additional, Manns, M.P., additional, Asselah, T., additional, Ferenci, P., additional, Pol, S., additional, Berg, T., additional, Lalezari, J., additional, Quinson, A.-M., additional, Datsenko, Y., additional, Scherer, J., additional, Yong, C.-L., additional, and Huang, F., additional

Published
2014
Full Text
View/download PDF

27. O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

Author

Lalezari, J., primary, Holland, L., additional, Glutzer, E., additional, Vig, P., additional, Elgadi, M., additional, Stern, J.O., additional, Colonno, R., additional, Halfon, S., additional, Ruby, E., additional, Huang, N., additional, Nash, E., additional, and Brown, N., additional

Published
2014
Full Text
View/download PDF

28. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS

Author

Boyer, D. S., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., Muccioli, C., Palestine, A. G., Perez, J. E. A., Territo, C., Andreu-Andreu, D., Deschennes, J. G., de Smet, M. D., Fisher, M., Gastaut, J. A., Gazzard, B. G., Lightman, S., Johnson, M. A., Klauss, V., Gumbel, H., Knospe, V., Mallolas-Masferrer, J., Cornish, M. J., Holland, G. N., Ransome, S. S., Tufail, A., Weisz, J. M., Crooke, S. T., Kishner, D. L., Frost, K. R., Hutscherson, S. L., Whitley, R. J., Chandler, J. W., Grillone, L. R., Hutcherson, S. L., Lanz, R., and Ophthalmology

Published
2002

29. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has

Author

Boyer, D. S., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., Muccioli, C., Palestine, A. G., Perez, J. E. A., Territo, C., Andreu-Andreu, D., Deschennes, J. G., de Smet, M. D., Fisher, M., Gastaut, J. A., Gazzard, B. G., Lightman, S., Johnson, M. A., Klauss, V., Gumbel, H., Knospe, V., Mallolas-Masferrer, J., Cornish, M. J., Holland, G. N., Ransome, S. S., Tufail, A., Weisz, J. M., Crooke, S. T., Kishner, D. L., Frost, K. R., Hutscherson, S. L., Whitley, R. J., Chandler, J. W., Grillone, L. R., Hutcherson, S. L., Lanz, R., and Ophthalmology

Published
2002

34. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

Author

Mitsuyasu, RT, Merigan, T, Carr, AD, Zack, J, Winters, M, Workman, C, Bloch, MT, Lalezari, J, Becker, S, Thornton, L, Akil, B, Khanlou, H, Finlayson, R, Mcfarlane, R, Smith, DE, Garsia, R, Ma, DD, Law, MG, Murray, JM, Von Kalle, C, Ely, JA, Patino, S, Knop, A, Wong, P, Todd, A, Haughton, M, Fuery, C, Marcpherson, J, Symonds, G, Evans, L, Pond, SM, Cooper, DA, Mitsuyasu, RT, Merigan, T, Carr, AD, Zack, J, Winters, M, Workman, C, Bloch, MT, Lalezari, J, Becker, S, Thornton, L, Akil, B, Khanlou, H, Finlayson, R, Mcfarlane, R, Smith, DE, Garsia, R, Ma, DD, Law, MG, Murray, JM, Von Kalle, C, Ely, JA, Patino, S, Knop, A, Wong, P, Todd, A, Haughton, M, Fuery, C, Marcpherson, J, Symonds, G, Evans, L, Pond, SM, and Cooper, DA

Published
2009

39. 1151 CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL

Author

Poordad, F., primary, Lalezari, J., additional, Lawitz, E., additional, Van Vlierberghe, H., additional, Shiffman, M., additional, Jacobson, I., additional, Kankam, M., additional, Araya, V., additional, Ghalib, R., additional, Ryan, M., additional, Bacon, B., additional, Flamm, S., additional, Godofsky, E., additional, Hazan, L., additional, Hinestrosa, F., additional, Michielsen, P., additional, Deltenre, P., additional, Robison, H., additional, Robarge, L., additional, and Olek, E., additional

Published
2012
Full Text
View/download PDF

40. 1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS

Author

Jacobson, I., primary, Lawitz, E., additional, Lalezari, J., additional, Crespo, I., additional, Davis, M., additional, Hassanein, T., additional, DeMicco, M., additional, Arora, S., additional, Gitlin, N., additional, Herring, R., additional, Nelson, D.R., additional, Anderson, J.K., additional, Hyland, R.H., additional, Mader, M., additional, Hindes, R., additional, Albanis, E., additional, Symonds, W.T., additional, and Berrey, M.M., additional

Published
2012
Full Text
View/download PDF

41. 1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS

Author

Kukolj, G., primary, Bethell, R., additional, Cartier, M., additional, Cote-Martin, A., additional, Lagace, L., additional, Marquis, M., additional, Triki, I., additional, Sulkowski, M., additional, Asselah, T., additional, Lalezari, J., additional, Ferenci, P., additional, Bocher, W.O., additional, Datsenko, Y., additional, Nehmiz, G., additional, Scherer, J., additional, Steinmann, G., additional, and Stern, J.O., additional

Published
2012
Full Text
View/download PDF

42. 60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

Author

Sulkowski, M.S., primary, Ceasu, E., additional, Asselah, T., additional, Caruntu, F.A., additional, Lalezari, J., additional, Ferenci, P., additional, Streinu-Cercel, A., additional, Fainboim, H., additional, Tanno, H., additional, Preotescu, L., additional, Leggett, B., additional, Bessone, F., additional, Mauss, S., additional, Stern, J.O., additional, Häfner, C., additional, Datsenko, Y., additional, Nehmiz, G., additional, Böcher, W., additional, and Steinmann, G., additional

Published
2011
Full Text
View/download PDF

43. 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

Author

Nelson, D.R., primary, Lalezari, J., additional, Lawitz, E., additional, Hassanein, T., additional, Kowdley, K., additional, Poordad, F., additional, Sheikh, A., additional, Afdhal, N., additional, Bernstein, D., additional, Dejesus, E., additional, Freilich, B., additional, Dieterich, D., additional, Jacobson, I., additional, Jensen, D., additional, Abrams, G.A., additional, Darling, J., additional, Rodriguez-Torres, M., additional, Reddy, R., additional, Sulkowski, M., additional, Bzowej, N., additional, Demicco, M., additional, Strohecker, J., additional, Hyland, R., additional, Mader, M., additional, Albanis, E., additional, Symonds, W.T., additional, and Berrey, M.M., additional

Published
2011
Full Text
View/download PDF

45. 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV

Author

Pol, S., primary, Berg, T., additional, Bonacini, M., additional, Schuchmann, M., additional, Lalezari, J., additional, Erhardt, A., additional, Bourliere, M., additional, Manns, M., additional, Stern, J.O., additional, Steinmann, G., additional, Yong, C.-L., additional, Scherer, J., additional, and Böcher, W., additional

Published
2011
Full Text
View/download PDF

46. 2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS

Author

Jacobson, I., primary, Pockros, P.J., additional, Lalezari, J., additional, Lawitz, E., additional, Rodriguez-Torres, M., additional, DeJesus, E., additional, Haas, F., additional, Martorell, C., additional, Pruitt, R., additional, Purohit, V., additional, Srinivasan, S., additional, Jagannatha, S., additional, Rana, K., additional, and Hammond, J., additional

Published
2010
Full Text
View/download PDF

47. 2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

Author

Lalezari, J., primary, Poordad, F., additional, Mehra, P., additional, Nguyen, T., additional, Dejesus, E., additional, Godofsky, E., additional, Patrick, G. Dubuc, additional, Chen, J., additional, Pietropaolo, K., additional, Zhou, X.-J., additional, Sullivan-Bólyai, J.Z., additional, and Mayers, D., additional

Published
2010
Full Text
View/download PDF

48. J Altern Complement Med: Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection

Author

Jariwalla, R.J., Lalezari, J., and Cenko, D.

Subjects
Glutathione -- Health aspects -- Physiological aspects -- Research, HIV infection -- Research -- Care and treatment, Health, Care and treatment, Physiological aspects, Research, Health aspects
Abstract

2008;14:139-146. OBJECTIVES: To determine whether supplementation with alpha-lipoic acid (ALA), a glutathione-replenishing disulfide, modulates whole blood total glutathione (GSH + GSSG) levels and improves lymphocyte function in human immunodeficiency virus [...]

Published
2008

49. 1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

Author

Jacobson, I., primary, Pockros, P., additional, Lalezari, J., additional, Lawitz, E., additional, Rodriguez-Torres, M., additional, DeJesus, E., additional, Haas, F., additional, Martorell, C., additional, Pruitt, R., additional, Durham, K., additional, Srinivasan, S., additional, Rosario, M., additional, Jagannatha, S., additional, and Hammond, J., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results